Targeting immunosuppression for cancer therapy
Mené sur un modèle murin, cette étude montre qu'une injection intratumorale de deux anticorps, anti-CTLA-4 et anti-OX-40, avec des lymphocytes Treg induit une réponse systémique du système immunitaire susceptible d'éradiquer des tumeurs distantes
Failing immunity has been acknowledged for its contribution to cancer development and progression. Recent clinical findings have provided payoffs for significant preclinical evaluation and refinement over the last 20 years, but many questions remain to be answered. In this issue of the JCI, Marabelle et al. describe a novel method for targeting the Tregs that infiltrate tumors, demonstrating that dampening the tumor immunosuppressive environment while activating innate antitumor immunity may be an effective approach to cancer treatment.
The Journal of Clinical Investigation , commentaire, 2012